Clinical Trial Update: NG101m Adjuvant Therapy in Glioblastoma Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of NG101m as adjuvant therapy for glioblastoma is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• NG101m

Snippet

Sponsor: NeuGATE Theranostics | Conditions: Glioblastoma Multiforme | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING